Kornimate/medical-research-clean huggingface dataset:
a study to evaluate the efficacy and safety of pemigatinib (incb054828) in subjects with urothelial carcinoma - (fight-201)

Conditions: UC (Urothelial Cancer)

Summary: the purpose of this study is to evaluate the overall response rate (orr) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring fgf/fgfr alterations.


Eligibility criteria:
inclusion criteria: * 20 years and older in japan * histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder. * eastern cooperative oncology group (ecog) performance status of 0-2. * life expectancy ≥ 12 weeks. * radiographically measurable per recist v1.1. * documented fgf/fgfr alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ecog status or 2) have insufficient renal function. exclusion criteria: * prior receipt of a selective fgfr inhibitor. * use of any potent cyp3a4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug. * inability or unwillingness to swallow pemigatinib or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib.

Keywords: urothelial carcinoma fibroblast growth factor (fgf) fibroblast growth factor receptor (fgfr) fgf/fgfr alterations
the role of central neck dissection in stage n0 papillary thyroid carcinoma

Conditions: Papillary Thyroid Cancer

Summary: the benefits of prophylactic central neck dissection (pcnd) remain controversial in clinically node-negative (cn0) papillary thyroid carcinoma (ptc). this study main goal is to investigate benefits of prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma.

papillary thyroid carcinoma (ptc) is the most common type of differentiated thyroid carcinoma. recurrence rate is still high. the standard management is total thyroidectomy. regional lymph node metastasis is noted in recurrent cases. some studies stated benefits of central neck dissection in orevention of recurrence and others said there is no benefits. so prophylactic central neck dissection (pcnd) remain controversial in clinically node-negative (cn0) papillary thyroid carcinoma (ptc).

Eligibility criteria:
inclusion criteria: * patients with papillary thyroid cancer with clinically node negative. exclusion criteria: * patients with clinical evidence of nodal metastases. * patients with a previous history of thyroidectomy. * patients with mixed-type papillary thyroid cancer.
value of radionuclide cisternography

Conditions: CSF Leak; Fistula

Summary: radionuclide cisternography (rc) is a nuclear medicine examination based on intrathecal injection of \[111in\]diethylenetriaminepentaacetic acid (\[111in\]dtpa). it is prescribed for two recommendations: detection of cerebrospinal fluid (csf) leak/fistula and diagnosis of normal pressure hydrocephalus. in the search part of csf leak/fistula, rc offers the benefit of a 24-hour study of csf unlike other reference tests. in addition to spect/ct imaging, the radiopharmacist performs sampling in nasal cavities and throat of the patient to collect a possible flow of csf. these samples are analysed by radioactivity measurements and bring an added value to the exam. the interest of this examination for management of csf leak/fistula remains unclear. the aim of this study is to identify and analyse results of all rc examinations performed since 2005 in the nuclear medicine department of the neurological hospital. the full analysis of patients will allow discussing the role of rc in management of csf leak/fistulae in clinical practice.


Eligibility criteria:
inclusion criteria: * patients who received a convocation for realization of rc (extraction with gera, software of nuclear medicine) exclusion criteria: * patients who received a convocation for realization of rc with "valve" protocol

Keywords: radionuclide cisternography csf leak imaging
sublingual sufentanil tablet system (ssts) versus intravenous patient controlled analgesia after back surgery.

Conditions: Pain, Postoperative

Summary: in this study, numeric rating scale (nrs) and side effects are measured after usage of a sublingual sufentanil tablet system (ssts) in comparison to intravenous patient controlled analgesia (pcia).

sublingual sufentanil tablet system (ssts) is compared in pain relief and side effect profile with the routinely used intravenous patient controlled analgesia (pcia) with morphine in the postoperative phase after back surgery. the common use of pcia with morphine is associated with a rather slow onset-time and active metabolites, with occurrence of potential harmful side effects as sedation and desaturation. this mono-centric project involving american society of anesthesiologists (asa) classification i-ii patients undergoing elective neurosurgery (laminectomy) are recruited. enrolled patients undergo numeric rating scale (nrs) and side effect questionnaire during the first 72h postoperatively.

Eligibility criteria:
inclusion criteria: * scheduled elective laminectomy or spinal fusion * american society anesthesiology classification system (asa) i-iii exclusion criteria: * chronic opioid use (\>3 months) * pregnancy * obstructive sleep apnea syndrome * supplemental oxygen therapy at home * postoperative use of non-steroidal anti-inflammatory or anti-neuropathic drugs

Keywords: numeric rating scale opioid side effects
cell therapy as treatment for cerebral palsy

Conditions: Cerebral Palsy

Summary: the purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.


Eligibility criteria:
inclusion criteria: * diagnosed cases of any type of cerebral palsy * age above 6 months. exclusion criteria: * presence of acute infections such as human immunodeficiency virus/hepatitis b virus/ hepatitis c virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia.

Keywords: cerebral palsy autologous bone marrow mononuclear cells stem cell
drainless robot-assisted minimally invasive esophagectomy

Conditions: Esophageal Cancer

Summary: the aim of this study is the evaluation of two different chest drain management strategies in patients undergoing robot-assisted minimally invasive esophagectomy (ramie) for esophageal cancer with regard to perioperative complications until discharge.the primary objective of the study is to investigate whether the intensity of postoperative pain can be significantly reduced by avoiding thoracic drains after ramie. we assume that this will influence secondary endpoints such as early recovery and length of hospital stay.


Eligibility criteria:
inclusion criteria: * patients scheduled for elective ramie for esophageal cancer with intrathoracic esophagogastrostomy (ivor-lewis) * american society of anesthesiologists (asa) score ≤ iii * eastern cooperative of oncology group (ecog) status ≤ ii * patient suitable for both surgical techniques * ability of subject to understand character and individual consequences of the clinical trial * written informed consent exclusion criteria: * open esophagectomy (either abdominal or during the thoracic part) * emergency operations * asa iv * ecog \> ii * chronic pain syndromes requiring routine analgesics * simultaneous lung resection * presence of contraindications to the use of epidural anesthesia (e.g. coagulopathies, anticoagulation or allergies) * participation in an interventional trial, which interferes with the outcome * impaired mental state

Keywords: esophagectomy enhanced recovery after surgery (eras) robot-assisted minimally invasive esophagectomy (ramie)
sugammadex dosage based on ideal body weight for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients

Conditions: Morbid Obesity

Summary: this randomized double blind clinical trial focuses on patients with body masse index ≥ 40 kg/m2, undergoing scheduled surgery. neuromuscular transmission monitoring at the adductor is performed using. anaesthesia is induced with anaesthesic and maintained with curare. at the end of the procedure, patients with profound neuromuscular blockade receive either 1 mg/kg, 2 mg/kg or 4 mg/kg sugammadex based on ideal body weight. a complete reversal failure is defined by a train of four ratio \< 0.9 within 10 min after administration of sugammadex or if recurarization occurs within 15 min after complete reversal success.


Eligibility criteria:
inclusion criteria: * general anaesthesia * neuromuscular blockade induce by rocuronium * body masse indice ≥ 40 kg/m2 * informed consent exclusion criteria: * contraindication to rocuronium or sugammadex * pregnant women * severe renal insufficiency

Keywords: general anaesthesia curarization with rocuronium
evaluation of quality of life, efficacy, and tolerance of duac® gel compared to differin® gel in the treatment of acne

Conditions: Acne Vulgaris

Summary: the objectives of this clinical trial are to compare the quality of life of the subjects, the efficacy and the tolerance of duac® gel (gel formulation with a combination of clindamycin phosphate \[equivalent to 1% clindamycin\] and 5% benzoyl peroxide), applied once daily, against differin® gel (gel with 0.1% adapalene), used once daily, in the treatment of mild to moderate acne vulgaris.

acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit. it is characterized by the formation of comedones, papules, pustules, nodules, cysts, maculae and scars, generally located on the face, chest and back. acne pathogenesis is recognized as multifactorial. acne vulgaris is the most common dermatological disorder. it affects approximately 85% individuals at some point in their lives, generally between 12 and 24 years of age. although acne is prevalent within this age range, it can persist for many years and its long-term physical and psychological implications can be significant. there are several medicinal products used to treat acne. however, the therapeutic challenge remains, therefore it is essential to continue investigating effective strategies for the treatment of this disease.

Eligibility criteria:
inclusion criteria: * subjects with mild to moderate acne vulgaris on the face,. * subjects of either sex aged between 12 and 39 years, inclusive. * subjects agreeing not to use sun-beds or undergo any uv light treatment for 4 weeks prior to entering the study and to minimize the amount of exposure to direct sunlight for the duration of the study. exclusion criteria: * women who are pregnant, breast-feeding, or sexually active with the potential to have children, and not using a contraception method that is safe from a medical point of view * subjects using anti-androgen containing contraceptives. * subjects who, during the past month, have received oral or topical steroids or antibiotics, or acne treatment of any type, including natural or artificial uv therapy. * subjects who have a history of hypersensitivity or idiosyncratic reaction to clindamycin phosphate, benzoyl peroxide, adapalene or any components of the medicinal products which will be used during the study. * subjects using, or having used in the past month, any significant concomitant medicinal product which might affect their acne, as judged by the investigator. * subjects with a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis. * subjects with a history of photosensitivity.

Keywords: differin quality of life acne duac acne vulgaris
evaluation of the hemodynamic significance of myocardial bridge by coronary blood fractional flow reserve

Conditions: Myocardial Bridge

Summary: this study clarified the influence of myocardial bridge on coronary hemodynamics by clarifying ffr and d-ffr to guide clinical intervention and treatment.

myocardial bridge is a congenital anatomical abnormality, which is generally considered to be a benign change, but individual can cause angina, myocardial infarction and even sudden death. previously, it was believed that the degree of myocardial ischemia induced by myocardial bridge was related to factors such as the location, length, and systolic stenosis of the myocardial bridge shown by coronary angiography.however, in recent years, more and more evidence has suggested that there is a high degree of mismatch between anatomical stenosis and its function.studies have shown that ffr and d-ffr can accurately evaluate the functional significance of stenotic lesions.this study intends to enroll patients who underwent coronary angiography due to chest pain and confirmed the left anterior descending artery (lad) simple myocardial bridge systolic stenosis ≥30%, and the pressure guide wire was used to measure the ffr and d-ffr of the myocardial bridge lesion under static and dobutamine stress.analyze the relationship between these functional parameters and the anatomical morphological characteristics of the myocardial bridge and other possible clinical influencing factors, and explore the influence of the morphological characteristics of the myocardial bridge on myocardial hemodynamics，so as to clarify the degree of myocardial bridge shown by angiography may induce obvious myocardial ischemia, which requires clinical intensive intervention.

Eligibility criteria:
inclusion criteria: * patients with chest pain aged ≥18 years old, regardless of gender; * coronary angiography shows a solitary myocardial bridge with systolic diameter stenosis ≥30% in lad; * have the ability to complete an ecg exercise test; * sign informed consent and are willing to participate in the intended study. exclusion criteria: * patients with acute coronary syndrome; * coronary angiography shows that the diameter of atherosclerosis in the non-myocardial bridge area of lad is ≥30%; * rca or lcx has severe fixed stenosis, diameter stenosis ≥70% or ffr\<0.75, and no interventional therapy is accepted; * hypertrophic obstructive cardiomyopathy or more than moderate heart valve disease; * atrial fibrillation or severe slow or rapid arrhythmia; * heart failure with nyha ≥ grade iii; * uncontrolled hypertension or systolic blood pressure \<100mmhg; * asthma or severe chronic obstructive pulmonary disease; * severe liver and kidney dysfunction; * allergic to contrast agents.
pascal pascal dynamic contour tonometer (dct) intraocular pressure and ocular pulse amplitude in patients with thyroid related orbitopathy: a comparison to goldmann tonometer and to muscles characteristics on ct scan

Conditions: Thyroid Related Orbitopathy

Summary: thyroid related orbitopathy (tro) is an autoimmune disease. clinical features include: orbital pressure pain, ocular soft tissue swelling, muscle enlargement around the eyeball, eyelid retraction and bulging of the eye anteriorly out of the orbit. in many cases, the cornea may become too dry, and as a result, corneal ulcers may form, which can become infected. in severe cases, damage to the optic nerve can occur secondary to optic nerve compression by enlarged muscles in the orbit. inflammation with soft tissue swelling occurs in the 1st stage of the disease. scar formation can occur in the 2nd phase. the muscles under and nasal to the eyeball are most commonly involved. in many patients, intra-ocular pressure (iop) can increase in primary. iop in upgaze (when looking up) can increase. goldmann applanation is the standard device to measure the iop. it measures the average iop (between the "systolic", when the heart contracts, to the diastolic iop, when the heart relaxes). pascal dynamic contour tonometer is a new device that can measure iop and ocular pulse amplitude (opa) which is the difference between diastolic iop and systolic iop. the choroid is a vascular layer inside the eyeball that feeds part of the retina (the retina is like the film in a non-digital camera). opa is suggestive of choroidal blood flow. iop measurements using pascal dynamic contour tonometer are less influenced by corneal thickness as opposed to goldmann applanation which measures higher values in thicker corneas. in the current study we are interested in measuring the relationships between measurements taken with goldmann applanation (iop) and those taken with the pascal dynamic contour tonometer (iop and opa). in addition, we will investigate the effect of orbital muscle enlargement on iop/opa following an up gaze position (looking up).


Eligibility criteria:
inclusion criteria: 1. age \> 18 yr 2. agree to participate in the study and willing to sign an informed consent exclusion criteria: 1. other ocular diseases (besides cataract and mild hypertensive retinopathy) 2. previous history of eye surgery besides cataract extraction and nd:yag laser capsulotomy 3. moderate to severe cataract that precludes fundus examination 4. pregnancy

Keywords: tro
intelligent cataract screening with portable slit-lamp

Conditions: Catarct Screening; Artificial Intelligence

Summary: based on the portable slit-lamp connected to the smartphone, the artificial intelligence machine learning algorithm is used to establish a cataract screening model by prospectively collecting the anterior segment photographic data, and a portable slit lamp intelligent screening referral model based on the smartphone connection is also established.


Eligibility criteria:
inclusion criteria: * 0 to 100 years old exclusion criteria: * (1) history of eye disease except for age-related cataracts (2) history of eye trauma or eye surgery (3) unable to cooperate with ophthalmology and general examination (4) individuals with incomplete information (5) unwilling to participate in this study
biomarkers of inflammation and endothelial dysfunction in patients with myocardial infarction with non-obstructive coronary arteries

Conditions: Myocardial Infarction; MINOCA; Inflammation; Biomarkers; Endothelial Dysfunction

Summary: around 10% of patients with myocardial infarction (mi) present with nonobstructive coronary arteries (minoca) which pathophysiology is often uncertain. the aim of the study is to evaluate inflammation and endothelial dysfunction biomarkers in minoca patients during both acute and stable phases, comparing them with those with mi and obstructive coronary arteries (micad).

prospective observational study in patients with myocardial infarction (mi) divided into two groups: mi with obstructive coronary arteries (micad) and mi with non-obstructive coronary arteries (minoca). levels of interleukin-6, tumor necrosis factor-alpha, high-sensitivity c- reactive protein, and asymmetric dimethylarginine will be determined at three time points: within the 24 hours from the onset of pain, discharge, and two months after mi. the association of biomarkers, normalized by peak troponin value, with the risk of minoca will be evaluated using logistic regression.

Eligibility criteria:
inclusion criteria: * patients admitted with myocardial infarction and undergo a coronariography * patients must sign informed consent. exclusion criteria: * patients who don´t sign informed consent
empagliflozin in acute heart failure

Conditions: Acute Heart Failure; Chronic Kidney Diseases

Summary: the objective is to study in a prospective, interventional, single arm, cohort study the potential synergistic diuretic effect of empagliflozin, in addition to furosemide, in hypervolemic patients admitted with acutely decompensated heart failure and diuretic resistance at the mcgill university health centre (muhc). the investigators hypothesize that the sodium-glucose cotransporter-2 (sglt-2) inhibitor empagliflozin will enhance the diuretic effect of furosemide in patients with acutely decompensated heart failure, moderate to advanced chronic kidney disease, and underlying diuretic resistance, as identified by the three-hour urine output post diuretic administration on the first day of the study, compared with furosemide alone.


Eligibility criteria:
inclusion criteria (all have to apply) : * moderate to advanced ckd, defined as an egfr \<45 ml/min/1.73m2; the average creatinine values over the last 12 months will be used to calculate baseline egfr. * acutely decompensated heart failure, defined as dyspnea at rest or with minimal physical activity, associated with at least one clinical sign of congestion and at least one objective measure of heart failure (pulmonary-capillary wedge pressure \>20 mm hg or evidence of pulmonary congestion on chest radiography or brain natriuretic peptide (bnp) level ≥400 pg/ml or n-terminal pro-bnp level ≥1000 pg/ml); * evidence of inadequate response to loop diuretics, defined as a urine output \< 1000 ml/24h or a weight loss \< 1kg /24h. for patients who have not received loop diuretics, a furosemide stress test can be conducted. * stable hemodynamics, defined as systolic blood pressure \>90 mmhg and/or mean arterial pressure \>65 mmhg in the absence of intravenous norepinephrine or epinephrine in the last 24 hours. exclusion criteria: * new use of a non-loop diuretic other than an mra * history of type 1 diabetes mellitus * euglycemic diabetic ketoacidosis * liver disease defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening * known hypersensitivity to sglt-2 inhibitors * use within the last 48 h of an sglt-2 inhibitor or a combined sglt-1 and sglt-2 inhibitor * maintenance dialysis or need for emergent renal replacement therapy * gastrointestinal surgery or gastrointestinal disorder that could interfere with trial medication absorption * recurrent severe genital or urinary tract infection * pregnancy or breastfeeding * any other clinical condition that would jeopardize patient safety while participating in this trial * patients with an acute rise in creatinine levels (acute cardiorenal syndrome) upon presentation will not be excluded.

Keywords: empagliflozin acute heart failure chronic kidney disease diuretic resistance furosemide